Indian Journal of Nuclear Medicine
Home | About IJNM | Search | Current Issue | Past Issues | Instructions | Ahead of Print | Online submissionLogin 
Indian Journal of Nuclear Medicine
  Editorial Board | Subscribe | Advertise | Contact
Users Online: 984 Print this page  Email this page Small font size Default font size Increase font size
Year : 2018  |  Volume : 33  |  Issue : 3  |  Page : 261-263

Prostate-specific membrane antigen imaging in recurrent medullary thyroid cancer: A new theranostic tracer in the offing?

Department of Nuclear Medicine, AIIMS, New Delhi, India

Correspondence Address:
Nishikant Avinash Damle
Department of Nuclear Medicine, AIIMS, Ansari Nagar, New Delhi - 110 029
Login to access the Email id

Source of Support: None, Conflict of Interest: None

DOI: 10.4103/ijnm.IJNM_10_18

Rights and Permissions

Prostate-specific membrane antigen (PSMA) expression has been shown in neovasculature of various malignancies. Recurrent medullary thyroid cancer (MTC) is difficult to treat. We present the findings on PSMA-positron emission tomography/computed tomography (PET/CT) of a 68-year-old man with MTC, who presented with a recurrent left paratracheal mass and rising calcitonin. The scan revealed significant uptake on PSMA imaging but not on 68Ga-DOTANOC PET/CT. 177Lu-PRRT is one of the therapeutic options in patients with recurrent MTC, but in this case was not possible due to lack of somatostatin receptor expression. Imaging evidence of PSMA expression alerts us to the potential use of 177Lu-DKFZ-PSMA-617 therapy in such patients.

Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)

 Article Access Statistics
    PDF Downloaded154    
    Comments [Add]    

Recommend this journal